Mayo Clinic launches data analytics initiative for drug discovery

An analytics-driven platform will be Mayo Clinic Platform's first venture, with an aim of using advanced data analytics and artificial intelligence to develop new treatments for disease, Rochester, Minn.-based Mayo Clinic announced Jan. 14.

The Clinical Data Analytics Platform will analyze deidentified data from Mayo Clinic, as well as other healthcare organizations and published studies and reports. The platform will prioritize data privacy, with participants from different organizations able to collaborate on the development of its underlying algorithms without sharing datasets.

The first of Mayo Clinic's partners for the initiative is Nference, a startup developing AI-enabled biomedical software in which Mayo Clinic Ventures recently invested. Integrating Nference's existing AI technology into the Clinical Data Analytics Platform will enable researchers to better identify drug targets and biomarkers, thus advancing the development of drugs to prevent, treat and cure complex diseases, according to a news release sent to Becker's Hospital Review.

Mayo Clinic Platform was established in 2019 to launch a portfolio of platform ventures, leveraging AI, connected devices and other emerging technologies, and the expertise of a network of partners. As of Jan. 1, Mayo Clinic Platform is led by John Halamka, MD, former longtime CIO of Boston-based Beth Israel Deaconess Medical Center.

More articles on data analytics:
Definitive Healthcare acquires analytics startup PatientFinder
Change Healthcare launches new solution for provider-payer data exchange
WakeMed to integrate Health Catalyst data management services

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Whitepapers

Featured Webinars